Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 13/20 | 0.70 |
| ▸ | TNKS | O95271 | 12/20 | 0.64 |
| ▸ | TNKS2 | Q9H2K2 | 12/20 | 0.64 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.64 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.51 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387263 | 0.82 | PARP1 (1.00) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL31208012 | 0.82 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL3423935 | 0.82 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL28763423 | 0.79 | PARP1 (0.66) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL9671521 | 0.79 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL4313736 | 0.79 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL15228758 | 0.79 | PARP1 (0.49) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL577862 | 0.79 | PARP1 (0.51) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL21072769 | 0.79 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2PARP14 | |
| SCHEMBL3423314 | 0.79 | TNKS (0.67) | PARP1TNKSTNKS2PARP2PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | PARP1 2477/4885TNKS 1771/4885TNKS2 2811/4885 |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | PARP1 1705/4885TNKS 3604/4885TNKS2 3815/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | PARP1 1906/4885TNKS 3690/4885TNKS2 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.